Find uplifting stories about heroes, innovations, and solutions
14532 results for "patient survival"
A breakthrough drug called daraxonrasib has shown it can extend survival in pancreatic cancer patients, one of medicine's toughest challenges. The announcement from Revolution Medicines marks what experts are calling a new era in treating this devastating disease.
For the first time in history, 70% of cancer patients are surviving their diagnosis, marking a stunning achievement in modern medicine. From Hollywood stars to everyday heroes, survivors are not just beating cancer but thriving in remarkable new chapters of their lives.
A personalized mRNA vaccine is helping pancreatic cancer patients survive six years and counting, with nearly 90% of responders still alive. For a disease with just 13% five-year survival, this breakthrough offers real hope.
Cancer specialists just published the first comprehensive guide to help patients thrive years after groundbreaking CAR-T cell therapy. The new roadmap tackles a crucial gap as more blood cancer patients survive longer than ever before.
A newly approved pill helped pancreatic cancer patients live nearly twice as long as those on standard chemotherapy, marking a historic breakthrough for one of the deadliest cancers. The FDA approved the targeted therapy after a global trial showed patients survived a median of 13.2 months.
When Black and white multiple myeloma patients receive the same modern treatments, they survive at equal rates. A Cleveland Clinic study proves access to care, not biology, drives health disparities.
An experimental once-daily pill nearly doubled survival time for patients with advanced pancreatic cancer, offering hope for one of the deadliest forms of the disease. The breakthrough targets a mutation present in over 90% of pancreatic tumors that scientists have struggled to treat for four decades.
After 40 years without progress, three experimental drugs are giving hope to pancreatic cancer patients, with one treatment doubling survival time from six months to over a year. The breakthroughs could transform one of the deadliest cancer diagnoses into a more manageable disease.
A daily pill for advanced pancreatic cancer nearly doubled survival time in a major trial, offering new hope for one of the deadliest cancers. Patients lived a median of 13.2 months compared to 6.7 months with standard chemotherapy.
A new pill targeting the KRAS mutation doubles survival time in pancreatic cancer patients, marking the biggest treatment breakthrough ever for one of the world's deadliest cancers. After 25 years of research and $17 million in funding, scientists are finally seeing progress on multiple fronts at once.
A groundbreaking pill targeting mutations in 90% of pancreatic cancer patients has approximately doubled survival time in clinical trials, offering new hope for one of medicine's toughest challenges. After decades of failed attempts, researchers have finally cracked a target once considered "undruggable."
A record number of Americans are living with cancer thanks to breakthrough targeted therapies that attack tumors based on their genetic signature. Two patients who've thrived for decades show how precision medicine is transforming cancer from a death sentence into a manageable condition.
Becca Valle was given months to live after a glioblastoma diagnosis, but a breakthrough ultrasound treatment helped her become part of a rare 10% who survive past five years. The experimental therapy could transform how doctors treat deadly brain cancers.
An experimental pancreatic cancer treatment that helped patients live nearly twice as long as standard chemotherapy is now reaching patients before formal FDA approval. Revolution Medicines began shipping daraxonrasib to physicians this week through a special early access program.
Seven in ten cancer patients now survive at least five years after diagnosis, a stunning achievement that reflects two decades of medical innovation. Survival rates have jumped across nearly every cancer type, turning once-grim diagnoses into real fighting chances.
A London hospital has quadrupled survival time for people with a rare eye cancer that spreads to the liver. Some patients are now living eight to ten years after treatment, where most previously survived less than two.
For the first time in history, seven out of 10 cancer patients in America now survive at least five years after diagnosis. A groundbreaking partnership in Connecticut shows how collaboration is making cutting-edge treatments available to patients everywhere, not just in major cities. #
Patients with brain metastases who received radiation tiles during surgery lived twice as long as those getting traditional post-surgery treatment. The breakthrough eliminates the weeks-long wait for radiation that often delays recovery.
A breakthrough oral medication helped multiple myeloma patients live 18 months without their cancer worsening, more than double the time compared to standard treatment. The results offer fresh hope for thousands of people whose cancer has stopped responding to other therapies.
Scientists at UCLA have achieved breakthrough results in treating advanced colorectal cancer, with a new combination therapy doubling two-year survival rates. The research team is also making major strides in prevention, from mailing free screening kits to developing powerful cancer vaccines.
Showing 20 of 14532